[{"id":"3fdf93b0-c47d-4574-b962-8f7ff8fdc8e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03231501","created_at":"2021-01-18T15:56:49.808Z","updated_at":"2024-07-02T16:36:44.143Z","phase":"Phase 1","brief_title":"HMPL-813 in Treating Patients With Glioblastoma","source_id_and_acronym":"NCT03231501","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epitinib (HMPL-813)"],"overall_status":"Unknown status","enrollment":" Enrollment 29","initiation":"Initiation: 01/26/2018","start_date":" 01/26/2018","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 08/31/2020","study_completion_date":" 08/31/2020","last_update_posted":"2020-06-16"}]